A Breakthrough Therapy designation for Sanofi’s hemophilia drug was given by the Food and Drug Administration on Wednesday.
A request for FDA approval of Efanesoctocog is expected this summer, according to the firm. A Fast Track designation in the United States and Orphan Drug classification in the United Kingdom have been awarded to the experimental treatment.
Delta Air Lines Raises Revenue Expectations
After the airline lifted its total and unit revenue expectations for the second quarter while lowering its capacity projection, Delta Air Lines Inc, (NYSE: DAL), saw its shares rise by 1.5 percent in premarket trade on Wednesday.
Expected revenue for the quarter ending in June is expected to be approximately 100 percent of pre-pandemic 2019 levels, up from 93 to 97 percent, while unit revenue is expected to be seven to eight percentage points better than previously expected.
Delta’s previous guidance was 93% to 97% of pre-pandemic 2019 levels. Cost per available seat mile (CASM) without fuel has been raised from around 17% to 20%, while ASM has been reduced from 82% to 83%.
The Delta fuel price forecast was raised from $3.20 to $3.35 to $3.60 to $3.70 per gallon due to the increase in the price of crude oil. It has risen 6.7% this year, while the U.S. Global Jets is down 2.9%, and the S&P 500 has dropped 13.3%.
The post Sanofi’s Experimental Haemophilia Drug Gets Breakthrough Designation From FDA appeared first on Best Stocks.
